ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

Conditions:   ANCA Associated Vasculitis;   Cardiovascular Diseases;   Kidney Diseases Intervention:   Drug: Sparsentan Sponsors:   University of Edinburgh;   Travere Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials